Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Clinical trial NCT07157514 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07157514
Sponsor: Actinium Pharmaceuticals
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Acute Leukemia Myeloid Leukemia Acute Myelogenous Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse Myelogenous Leukemia Myelogenous Leukemia, Acute Myelogenous Leukemia in Relapse Transplant-Related Disorder Allogeneic Disease Refractory AML

Start date: 2026-01-01
Primary completion: 2029-02-01
Enrollment: 306

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.